SpyGlass Ophthalmics: Closes $27.5M in Series B Financing

January 11, 2021

676

SpyGlass Ophthalmics: Closes $27.5M in Series B Financing

Must read

Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

SpyGlass Ophthalmics, a Mission Viejo, CA-based ophthalmic therapeutics company, secured $27.5m in Series B financing
The round led by Vensana Capital with participation from existing investor New Enterprise Associates
In conjunction with the funding, NEA Principal Dr. Tak Cheung, formerly a board observer, will now joining the SpyGlass board
The company also intends to use the funds to further advance the development efforts of platform technology
SpyGlass Ophthalmics focused on the development of novel treatments for chronic ophthalmic diseases
The technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and spun off-campus post-Series A funding